公开(公告)号：US20150065512A1

公开(公告)日：2015-03-05

申请号：US14535556

申请日：2014-11-07

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/4985 ,  A61K31/357

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Abstract translation: 本文描述了式（A）和（B）的化合物及其用于治疗由钠 - 葡萄糖转运蛋白抑制剂（特别是SGLT2抑制剂）介导的疾病，病症和/或病症的用途。

公开(公告)号：US10813942B2

公开(公告)日：2020-10-27

申请号：US16450649

申请日：2019-06-24

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D493/08 ,  A61K31/357 ,  A61K31/706 ,  C07D309/14 ,  C07H13/04 ,  C07H15/26 ,  A61K47/64 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/46 ,  C07H15/08 ,  C07H15/12 ,  C07K5/065

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20170165284A1

公开(公告)日：2017-06-15

申请号：US15434508

申请日：2017-02-16

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: A61K31/706 ,  A61K31/7056 ,  A61K31/7008

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20160207953A1

公开(公告)日：2016-07-21

申请号：US15093178

申请日：2016-04-07

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07H15/08 ,  A61K31/7008 ,  C07H15/26 ,  A61K38/46 ,  C07H15/12 ,  A61K31/706 ,  C07K5/065 ,  C07H13/04 ,  A61K31/7056

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20150065565A1

公开(公告)日：2015-03-05

申请号：US14535613

申请日：2014-11-07

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K31/155

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

公开(公告)号：US20150065513A1

公开(公告)日：2015-03-05

申请号：US14535630

申请日：2014-11-07

Applicant: PFIZER INC.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K31/155 ,  C07D493/08 ,  A61K31/4985

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

公开(公告)号：US20170137801A1

公开(公告)日：2017-05-18

申请号：US15347339

申请日：2016-11-09

Applicant: Pfizer Inc. ,  The Regents of the University of California

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Aaron Thuma ,  Jennifer A. Doudna ,  Romain Rouet

IPC: C12N9/96 ,  C12N15/90 ,  C12N9/22

CPC classification number: C12N9/96 ,  A61K47/549 ,  C12N9/22 ,  C12N15/907

Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US09617293B2

公开(公告)日：2017-04-11

申请号：US15093178

申请日：2016-04-07

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D493/08 ,  A61K31/35 ,  C07H15/08 ,  C07D309/14 ,  C07H13/04 ,  C07H15/26 ,  A61K31/7008 ,  A61K31/7056 ,  A61K31/706 ,  A61K38/46 ,  C07H15/12 ,  C07K5/065

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20150329555A1

公开(公告)日：2015-11-19

申请号：US14714484

申请日：2015-05-18

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D493/08 ,  C07D309/14

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

Abstract translation: 本文描述了式（A）的化合物及其用于治疗由药物组合物介导的疾病，病症和/或病症及其作为唾液酸糖蛋白受体（ASGPR）靶向剂的用途的用途。

公开(公告)号：US20130225487A1

公开(公告)日：2013-08-29

申请号：US13796339

申请日：2013-03-12

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K45/06

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).